EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Proton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis,
erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer),
and heartburn. Despite their efficacy, their use has been implicated in possibly causing
fragility fractures (osteoporosis), hypomagnesemia (magnesium deficiency) and increased risk
of chronic kidney disease (CKD). The current trial represents the investigators ongoing
effort to discern whether these complications could be averted by effervescent calcium
magnesium citrate (EffCaMgCit).